On Mar. 24, 2020, Bausch Health announced it had donated medicines and health care products to assist in the global fight against COVID-19 while also pursuing research to determine if products in their existing portfolio may offer valuable treatment option.

In the U.S., the Company’s subsidiary Salix Pharmaceuticals is working to initiate investigative trials to evaluate XIFAXANﾮ (rifaximin) in combination with established therapies, supportive care and other investigative therapies to potentially address the symptoms of gastrointestinal distress and pulmonary compromise associated with COVID-19 infection.